Congress Already Impacting Industry Drug Pricing Abuses, Valeant Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant investor, board member Ackman, outgoing CEO Pearson suggest congressional hearings have made a significant impression on biopharma industry.